As of 2024-07-27, the EV/EBITDA ratio of Cara Therapeutics Inc (CARA) is 0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CARA's latest enterprise value is -26.63 mil USD. CARA's TTM EBITDA according to its financial statements is -123.52 mil USD. Dividing these 2 quantities gives us the above CARA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 17.1x | 13.3x |
| Forward P/E multiples | 17.2x - 21.3x | 20.4x |
| Fair Price | (37.99) - (37.68) | (37.15) |
| Upside | -10302.4% - -10217.5% | -10074.9% |
| Date | EV/EBITDA |
| 2024-07-26 | 0.22 |
| 2024-07-25 | 0.22 |
| 2024-07-24 | 0.22 |
| 2024-07-23 | 0.21 |
| 2024-07-22 | 0.22 |
| 2024-07-19 | 0.23 |
| 2024-07-18 | 0.23 |
| 2024-07-17 | 0.23 |
| 2024-07-16 | 0.22 |
| 2024-07-15 | 0.23 |
| 2024-07-12 | 0.22 |
| 2024-07-11 | 0.22 |
| 2024-07-10 | 0.25 |
| 2024-07-09 | 0.25 |
| 2024-07-08 | 0.25 |
| 2024-07-05 | 0.25 |
| 2024-07-03 | 0.26 |
| 2024-07-02 | 0.26 |
| 2024-07-01 | 0.26 |
| 2024-06-28 | 0.27 |
| 2024-06-27 | 0.25 |
| 2024-06-26 | 0.25 |
| 2024-06-25 | 0.23 |
| 2024-06-24 | 0.23 |
| 2024-06-21 | 0.26 |
| 2024-06-20 | 0.27 |
| 2024-06-18 | 0.27 |
| 2024-06-17 | 0.27 |
| 2024-06-14 | 0.23 |
| 2024-06-13 | 0.18 |
| 2024-06-12 | 0.08 |
| 2024-06-11 | 0.09 |
| 2024-06-10 | 0.08 |
| 2024-06-07 | 0.10 |
| 2024-06-06 | 0.10 |
| 2024-06-05 | 0.07 |
| 2024-06-04 | 0.09 |
| 2024-06-03 | 0.08 |
| 2024-05-31 | 0.09 |
| 2024-05-30 | 0.12 |
| 2024-05-29 | 0.11 |
| 2024-05-28 | 0.08 |
| 2024-05-24 | 0.08 |
| 2024-05-23 | 0.06 |
| 2024-05-22 | 0.04 |
| 2024-05-21 | 0.05 |
| 2024-05-20 | 0.05 |
| 2024-05-17 | 0.05 |
| 2024-05-16 | 0.02 |
| 2024-05-15 | 0.04 |